马来酸曲美布汀联合门诊森田疗法治疗肠易激综合征的临床研究

目的 :观察马来酸曲美布汀联合门诊森田疗法治疗肠易激综合征 (irritablebowelsyndrome ,IBS)的临床疗效。方法 :10 8例患者随机分为 2组。马来酸曲美布汀组 5 4例 :2 0 0mg马来酸曲美布汀 ,po ,tid ,配合门诊森田心理疗法 ,治疗前、后以焦虑自评量表 (SAS)和抑郁自评量表 (SDS)评定疗效 ;对照组5 4例 :仅用 2 0 0mg马来酸曲美布汀 ,po ,tid ,2组疗程均为 4周。结果 :马来酸曲美布汀组和对照组总有效率分别为 87.0 4 %与 72 .2 2 % ,马来酸曲美布汀组明显优于对照组 (P <0 .0 5 )。马来酸曲美布汀组治疗后SAS、SDS评分与对照组比较均有明显下降(P <0 .0 1)。马来酸曲美布汀组 6月复发率与对照组比较明显降低 (P <0 .0 1)。结论 :马来酸曲美布汀联合门诊森田疗法是治疗肠易激综合征更有效的治疗方法。

Clinical efficacy of trimebutine maleate combined with Morita therapy in treatment of patients with irritable bowel syndrome

AIM: To investigate the clinical efficacy of trimebutine maleate combined with Morita therapy in the treatment of patients with irritable bowel syndrome (IBS). METHODS: 108 patients were randomly assigned to two groups. Trimebutine maleate group (n=54) was given trimebutine maleate 200 mg, po, tid, combined with Mortia therapy. The patients were analyzed by self rating anxiety scale (SAS) and self rating depression scale (SDS) before and after the treatment. Control group (n=54) was only given trimebutine maleate 200 mg, po, tid. The course was 4 weeks. RESULTS: The total efficacy rates were 87.04 % and 72.22 % in trimebutine maleate group and in control group, respectively. The therapeutic effects in trimebutine maleate group were better than those in the control group (P< 0.05 ). The scores of SAS and SDS in trimebutine maleate group decreased significantly after the treatment (P< 0.01 ). There were significant difference in recurrence rates between in trimebutine maleate group and in control group (P< 0.01 ). CONCLUSION: The combination of trimebutine maleate combined with Morita therapy is an effective approach in treating IBS.